SUCCESSFUL MANAGEMENT OF LOW-STAGE NEUROBLASTOMA WITHOUT ADJUVANT THERAPIES - A COMPARISON OF 2 DECADES, 1972 THROUGH 1981 AND 1982 THROUGH1992, IN A SINGLE INSTITUTION
Ae. Evans et al., SUCCESSFUL MANAGEMENT OF LOW-STAGE NEUROBLASTOMA WITHOUT ADJUVANT THERAPIES - A COMPARISON OF 2 DECADES, 1972 THROUGH 1981 AND 1982 THROUGH1992, IN A SINGLE INSTITUTION, Journal of clinical oncology, 14(9), 1996, pp. 2504-2510
Purpose: A review was undertaken of 119 children seen at the Children'
s Hospital of Philadelphia between 1972 and 1992 to assess the impact
of adjuvant therapies for patients with low-stage neuroblastoma (NBL).
Patients and Methods: Twenty-one of 119 International Neuroblastoma S
taging System (INSS) stage 1, 2a, 2b, and 4s patients seen received in
itial adjuvant treatment postoperatively and 98 did not. The patients
were further subdivided according to decade, age, presence of residual
disease, and lymph node status. Outcomes were then compared. Results:
The event-free survival (EFS) rate for those who received adjuvant th
erapy was 52% versus 86% for those who did not. The 5-year survival ra
te was 68% and 94%, respectively. Age (< or > 12 months), extent of re
sidual disease, and status of lymph nodes did not influence survival,
Over the two decades, the reasons for selecting treatment changed as n
ew and powerful additional prognostic factors were identified; 71% of
patients received no adjuvant treatment in the first decade, compared
with 90% in the second, EFS rates for untreated patients by decade wer
e 79% and 89%, and 5-year survival rates were 85% and 98%, respectivel
y. Conclusion: It is possible to define most low-stage NBL as favorabl
e-even in patients with positive lymph nodes and gross residual diseas
e-and to omit initial adjuvant treatments successfully. (C) 1996 by Am
erican Society of Clinical Oncology.